Darvishi Mohammad, Nouri Majid, Rahimi Rasoul, Heidari-Soureshjani Saeid, Hashemi Rafsanjani Seyed Mahmoud Reza
Infectious Diseases and Tropical Medicine Research Center (IDTMRC), School of Aerospace and Subaquatic Medicine, Aja University of Medical Sciences, Tehran, Iran.
Infectious Diseases and Tropical Medicine Research Center (IDTMRC), Aja University of Medical Sciences, Tehran, Iran.
Curr Mol Med. 2025;25(5):589-604. doi: 10.2174/0115665240284347240125072555.
Resveratrol (RSV) is used for the treatment of various diseases due to their anti-inflammatory and antioxidant activities. However, its beneficial aspects on viral hepatitis have been less investigated.
This report reviews the impact of resveratrol on viral hepatitis and chronic viral hepatitis-related hepatocellular carcinoma (HCC).
The systematic review was performed and reported according to the PRISMA 2020 statement. Several core databases, such as Cochrane Library, PubMed, Web of Science, EMBASE, and Scopus, were used for search on September 6, 2023. After extraction of the data, the desired information of the full text of the studies was recorded in Excel, and the outcomes and mechanisms were reviewed.
RSV inhibits viral replication through anti-HCV NS3 helicase activity, maintains redox homeostasis via glutathione (GSH) synthesis, improves T and B cell activity, and suppresses miR-155 expression. It also enhances viral replication by enhancing hepatitis C virus (HCV) RNA transcription, activating sirtuin-1 (SIRT1), which can increase peroxisome proliferator-activated receptor (PPAR), and SIRT1 activates the HBV X protein (HBx). Moreover, RSV is responsible for hepatitis-related HCC proliferation via suppression of mammalian target of rapamycin (mTOR), SIRT1 up-regulation, inhibiting expression of HBx, and reducing expression of cyclin D1.
Despite the promising properties of RSV in inhibiting hepatitis-related HCC cell proliferation, its antiviral effects in viral hepatitis are controversial. The antihepatitis behaviors of RSV are mainly dose-dependent, and in some studies, activating some hepatoprotective pathways increases the transcription and replication of chronic HBV and HCV. Therefore, healthcare providers should be aware of viral hepatitis before using RSV supplements.
白藜芦醇（RSV）因其抗炎和抗氧化活性而被用于治疗多种疾病。然而，其对病毒性肝炎的有益作用研究较少。
本报告综述白藜芦醇对病毒性肝炎及慢性病毒性肝炎相关肝细胞癌（HCC）的影响。
根据PRISMA 2020声明进行系统评价并报告。2023年9月6日，使用了几个核心数据库，如Cochrane图书馆、PubMed、科学网、EMBASE和Scopus进行检索。提取数据后，将研究全文的所需信息记录在Excel中，并对结果和机制进行综述。
RSV通过抗丙型肝炎病毒（HCV）NS3解旋酶活性抑制病毒复制，通过谷胱甘肽（GSH）合成维持氧化还原稳态，改善T和B细胞活性，并抑制miR-155表达。它还通过增强丙型肝炎病毒（HCV）RNA转录、激活沉默调节蛋白-1（SIRT1）来增强病毒复制，SIRT1可增加过氧化物酶体增殖物激活受体（PPAR），且SIRT1激活乙型肝炎病毒X蛋白（HBx）。此外，RSV通过抑制雷帕霉素靶蛋白（mTOR）、上调SIRT1、抑制HBx表达和降低细胞周期蛋白D1表达来促进肝炎相关HCC增殖。
尽管RSV在抑制肝炎相关HCC细胞增殖方面具有良好的特性，但其在病毒性肝炎中的抗病毒作用仍存在争议。RSV的抗肝炎行为主要取决于剂量，并且在一些研究中，激活某些肝脏保护途径会增加慢性乙型肝炎病毒和丙型肝炎病毒的转录和复制。因此，医疗保健提供者在使用RSV补充剂之前应了解病毒性肝炎。
